697 related articles for article (PubMed ID: 31345397)
1. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
2. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
4. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
Rasmussen JH; Grønhøj C; Håkansson K; Friborg J; Andersen E; Lelkaitis G; Klussmann JP; Wittekindt C; Wagner S; Vogelius IR; von Buchwald C
Ann Oncol; 2019 Apr; 30(4):629-636. PubMed ID: 30657857
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
6. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
[TBL] [Abstract][Full Text] [Related]
7. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
8. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
9. Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
Contrera KJ; Smile TD; Mahomva C; Wei W; Adelstein DJ; Broughman JR; Burkey BB; Geiger JL; Joshi NP; Ku JA; Lamarre ED; Lorenz RR; Prendes BL; Scharpf J; Schwartzman LM; Woody NM; Xiong D; Koyfman SA
Oral Oncol; 2020 Dec; 111():105030. PubMed ID: 33038751
[TBL] [Abstract][Full Text] [Related]
10. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
13. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
14. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
[TBL] [Abstract][Full Text] [Related]
15. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
16. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
17. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
Lin TA; Garden AS; Elhalawani H; Elgohari B; Jethanandani A; Ng SP; Mohamed AS; Frank SJ; Glisson BS; Debnam JM; Sturgis EM; Phan J; Reddy JP; Fuller CD; Morrison WH; Skinner HD; Rosenthal DI; Gunn GB
Cancer; 2019 May; 125(9):1536-1546. PubMed ID: 30620385
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
Chen MM; Colevas AD; Megwalu U; Divi V
Oral Oncol; 2018 Sep; 84():71-75. PubMed ID: 30115479
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
